PTX News Alert Pernix Therapeutics Holdings Inc. (PTX) 10.95

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 7:22 PM

Pernix Therapeutics Holdings Inc. (PTX) 10.95 $PTX

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PGNX: 6.45 (-0.16), ICUI: 84.95 (+0.22), CDZI: 10.50 (-0.18), INSY: 38.71 (-0.94), PCMI: 8.94 (+0.14), PTX: 10.95 (-0.10), CYAN: 6.52 (+0.54), ACHN: 13.49 (-1.36), AGIO: 86.49 (-0.38), LIOX: 5.25 (-0.18), PLNR: 6.67 (-0.48)

Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST

FSM: 4.18 (-0.30), HEAR: 4.03 (+0.02), JRJC: 6.56 (-0.64), CVO: 1.90 (-0.01), AAOI: 12.10 (-0.22), UNIS: 3.00 (-0.04), HIIQ: 8.46 (-0.24), CYAN: 6.52 (+0.54), PTX: 10.95 (-0.10), TRMR: 2.77 (-0.17), PRKR: 1.10 (+0.02), SUMR: 2.91 (+0.11), VSLR: 11.70 (-0.63), RVP: 3.71 (-0.39), ASCMA: 51.98 (+0.67), ICUI: 84.95 (+0.22), CALL: 8.34 (-0.34), DMD: 5.34 (-0.36), AST: 3.89 (-0.14), ASEI: 44.31 (-0.46)

Pernix Therapeutics Holdings' (PTX) CEO Douglas Drysdale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:46PM CST

PTX: 10.95 (-0.10)

Pernix Therapeutics ups revenues 72% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:15PM CST

PTX: 10.95 (-0.10)

Pernix Therapeutics Holdings (PTX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:55AM CST

PTX: 10.95 (-0.10)

Pernix Therapeutics misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:09AM CST

PTX: 10.95 (-0.10)

Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance
Business Wire - Mon Nov 10, 7:01AM CST
--Company Reiterates Full Year 2014 and 2015 Guidance
PTX: 10.95 (-0.10)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.77 (-0.18), PTX: 10.95 (-0.10), AKRX: 37.68 (+2.25), RPRX: 9.60 (+0.17), NKTR: 13.86 (-0.11)

Pernix reports November 10
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 10:53AM CDT

PTX: 10.95 (-0.10)

Pernix Therapeutics to Report Q3 2014 Financial Results
Business Wire - Mon Oct 27, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST.
PTX: 10.95 (-0.10)

5 Stocks Under $10 Set to Soar
at The Street - Fri Oct 17, 8:41AM CDT
These under-$10 stocks look ready to trade higher from current levels.
GOMO: 6.61 (+0.61), ARWR: 6.22 (-0.31), PTX: 10.95 (-0.10), ADHD: 3.60 (-0.02), ZQK: 2.04 (-0.04), SALT: 4.09 (-0.31)

3 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 15, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HGG: 6.16 (+0.26), PTX: 10.95 (-0.10), IVAC: 7.64 (-0.24)

5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Sep 26, 1:16PM CDT
These under-$10 stocks look ready to trade higher from current levels.
PTX: 10.95 (-0.10), TGS: 3.57 (-0.05), RPRX: 9.60 (+0.17), NQ: 7.27 (-0.48), CVGI: 6.55 (-0.06)

Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
Business Wire - Wed Aug 20, 7:01AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"

, a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet(R) on May 14. Pernix's expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet(R). The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition.
PTX: 10.95 (-0.10), GSK: 45.66 (+0.04), POZN: 9.29 (-0.10)

POZEN Announces U.S. Rights For TREXIMET(R) Have Been Acquired by Pernix Therapeutics
Business Wire - Wed Aug 20, 7:00AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's (GSK) rights to Treximet(R) (sumatriptan / naproxen sodium) have been acquired by Pernix Therapeutics Holdings, Inc. (Pernix). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development.
PTX: 10.95 (-0.10), GSK: 45.66 (+0.04), POZN: 9.29 (-0.10)

Pernix Therapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"

(NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014.
PTX: 10.95 (-0.10)

Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed
PR Newswire - Thu Aug 07, 8:20AM CDT
On Wednesday, August 6, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 16,443.34, and the S&P 500 closed the day flat at 1,920.24. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, while the index has advanced 5.09% in the previous three months. Investor-Edge has initiated coverage on the following equities: Theravance Inc. (NASDAQ: THRX), Akorn Inc. (NASDAQ: AKRX), Endo International PLC (NASDAQ: ENDP), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), and Depomed Inc. (NASDAQ: DEPO). Free research on these five companies can be accessed at:
ENDP: 67.10 (-0.79), THRXV: 28.00 (+7.07), PTX: 10.95 (-0.10), AKRX: 37.68 (+2.25), DEPO: 14.78 (+0.13), THRX: 13.34 (+0.02)

Closing for Pernix Transaction to Acquire Treximet(R) Tablets for Migraine from GSK Delayed
Business Wire - Mon Aug 04, 8:15AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"

, a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue.
PTX: 10.95 (-0.10), GSK: 45.66 (+0.04)

Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014
Business Wire - Fri Jul 25, 8:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
PTX: 10.95 (-0.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Airswift's Strategic Acquisition Boosts U.S. Energy Presence

What's Driving Airswift's Latest Expansion? Airswift just dropped a bombshell by snapping up key businesses from New Tech Global (NTG), marking a serious power move in the U.S. energy sector. Now, what does this actually mean for investors? In blunt terms: they're muscling up their contractor base by a meaty 30%. That's no small feat. It's a calculated step to ace the...

Beetles Gel Polish Unveils Vibrant Fall Nail Carnival

Beetles Gel Polish Launches Fall Nail Carnival Here comes a new twist on fall fashion, and no, it ain’t your grandma's knitted sweater. We're talking nail polish—a vibrant, flashy ordeal brought to you by Beetles Gel Polish with their Fall Nail Carnival. They're rolling out this spectacle not just for your visions of grandeur nail ideas, but for those seeking deals...

Celebrating Appalachian Soul with Aristotle Jones

Igniting a Celebration of Appalachian Soul Now here's a sound that hits you right in the gut. Aristotle Jones, known out there as the 'Appalachian Soul Man,' is making a big move. He's laying out the plan to make July the Appalachian Soul Month. This fellow isn't shy about celebrating the deep roots of Appalachian music, dropping his album Appalachian Soul Power and a new...

Omneky Integrates AI Growth Agent With Slack for Ads

Omneky's New Move: AI Growth Agent Meets Slack Picture this: You've got a marketing team hustling in the digital age, and now they've got a new ally. Omneky, the big-wig in autonomous AI growth, has snuck its AI Growth Agent right into Slack. This isn't just a party trick during Dreamforce week in San Francisco. This is Omneky throwing another cog into the advertising...

Guaranteed Roof Expands with EM Exteriors through LB Capital

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

AI Coding Models' Self-Reporting Under Scrutiny with New Tool

Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

Bud Ecosystem Debuts AIOS, Aims to Slash Costs

AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...

American Savings Bank Surges 6% on NYSE Debut

American Savings Bank Lands with a Bang on NYSE Who would have thought American Savings Bank's (NYSE: ASBH) entry onto the stock market would start with such gusto? It's not every day you see a debut that impressive, with shares soaring 6.25% right out of the gate. Guess it's safe to say the folks over at ASBH did something right in the lead-up to their NYSE launch. CEO...

Andover Audio's FreePlay: Stereo Sound Goes Portable

If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...